Literature DB >> 22106218

Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.

Thomas Grau1, Petra Selchow, Marcel Tigges, Reto Burri, Marc Gitzinger, Erik C Böttger, Martin Fussenegger, Peter Sander.   

Abstract

Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects of ethionamide, isoxyl, and thiacetazone in Mycobacterium tuberculosis strains with resistance to ETH due to inhA promoter mutations but not ethA mutations.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22106218      PMCID： PMC3264283          DOI： 10.1128/AAC.05649-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  F Brossier; N Veziris; C Truffot-Pernot; V Jarlier; W Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

2.  N-D-aldopentofuranosyl-N'-[p-(isoamyloxy)phenyl]-thiourea derivatives: potential anti-TB therapeutic agents.

Authors:  Avraham Liav; Shiva K Angala; Patrick J Brennan; Mary Jackson
Journal:  Bioorg Med Chem Lett       Date:  2008-03-14       Impact factor: 2.823

3.  Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis.

Authors:  A E DeBarber; K Mdluli; M Bosman; L G Bekker; C E Barry
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

4.  inhA promoter mutations: a gateway to extensively drug-resistant tuberculosis in South Africa?

Authors:  B Müller; E M Streicher; K G P Hoek; M Tait; A Trollip; M E Bosman; G J Coetzee; E M Chabula-Nxiweni; E Hoosain; N C Gey van Pittius; T C Victor; P D van Helden; R M Warren
Journal:  Int J Tuberc Lung Dis       Date:  2011-03       Impact factor: 2.373

5.  Activation of the pro-drug ethionamide is regulated in mycobacteria.

Authors:  A R Baulard; J C Betts; J Engohang-Ndong; S Quan; R A McAdam; P J Brennan; C Locht; G S Besra
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

6.  A synthetic mammalian gene circuit reveals antituberculosis compounds.

Authors:  Wilfried Weber; Ronald Schoenmakers; Bettina Keller; Marc Gitzinger; Thomas Grau; Marie Daoud-El Baba; Peter Sander; Martin Fussenegger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-09       Impact factor: 11.205

Review 7.  The mechanism of isoniazid killing: clarity through the scope of genetics.

Authors:  Catherine Vilchèze; William R Jacobs
Journal:  Annu Rev Microbiol       Date:  2007       Impact factor: 15.500

8.  Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.

Authors:  Burkhard Springer; Katja Lucke; Romana Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2009-04-01       Impact factor: 5.948

9.  Synthetic EthR inhibitors boost antituberculous activity of ethionamide.

Authors:  Nicolas Willand; Bertrand Dirié; Xavier Carette; Pablo Bifani; Amit Singhal; Matthieu Desroses; Florence Leroux; Eve Willery; Vanessa Mathys; Rebecca Déprez-Poulain; Guy Delcroix; Frédéric Frénois; Marc Aumercier; Camille Locht; Vincent Villeret; Benoit Déprez; Alain R Baulard
Journal:  Nat Med       Date:  2009-05-03       Impact factor: 53.440

10.  Mechanism of thioamide drug action against tuberculosis and leprosy.

Authors:  Feng Wang; Robert Langley; Gulcin Gulten; Lynn G Dover; Gurdyal S Besra; William R Jacobs; James C Sacchettini
Journal:  J Exp Med       Date:  2007-01-16       Impact factor: 14.307
View more
  7 in total

Review 1.  Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.

Authors:  Kerstin A Wolff; Liem Nguyen
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091

Review 2.  Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.

Authors:  Mary Jackson; Michael R McNeil; Patrick J Brennan
Journal:  Future Microbiol       Date:  2013-07       Impact factor: 3.165

Review 3.  New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.

Authors:  E Jeffrey North; Mary Jackson; Richard E Lee
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

4.  5-Fluorouracil blocks quorum-sensing of biofilm-embedded methicillin-resistant Staphylococcus aureus in mice.

Authors:  Ferdinand Sedlmayer; Anne-Kathrin Woischnig; Vincent Unterreiner; Florian Fuchs; Daniel Baeschlin; Nina Khanna; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2021-07-21       Impact factor: 19.160

5.  Chemical analysis of the Chinese liquor Luzhoulaojiao by comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry.

Authors:  Feng Yao; Bin Yi; Caihong Shen; Fei Tao; Yumin Liu; Zhixin Lin; Ping Xu
Journal:  Sci Rep       Date:  2015-04-10       Impact factor: 4.379

Review 6.  A literature survey on antimicrobial and immune-modulatory effects of butyrate revealing non-antibiotic approaches to tackle bacterial infections.

Authors:  Ke Du; Stefan Bereswill; Markus M Heimesaat
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2021-03-17

7.  How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance.

Authors:  Thomas Maitre; Florence Morel; Florence Brossier; Wladimir Sougakoff; Jéremy Jaffre; Sokleaph Cheng; Nicolas Veziris; Alexandra Aubry
Journal:  Microorganisms       Date:  2022-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.